Exit Options for John Hancock Bond and Corporate Finance Group: Hanover Communications In... - 28 Strategic Investors
- or -
Signing up for Aurigin is fast and free. Get instant access to middle market transactions from around the globe.
Fill out the details below to sign up
I agree to all Aurigin Terms & Services and Privacy Policy
You have successfully signed up.
We have sent you a verification email. Please click on the link in the email to verify your account and access deals on Aurigin.
Please connect with us to get access to Impact Vault
Your request has been sent. Someone from the Aurigin team will be in touch with you shortly.
Corporate Development Head
Hungary
US$10M to 500M
More than 50%, 100%
US$5M to 200M
US$1M to 20M
Direct Party
Hungarian based Pharma company looking to acquire companies having new therapeutic systems including cardiovascular, Central nervous system, Gastroenterology, dermatology and gynecology (OTC & RX), Oncology, Bio-similar drugs(autoimmune, oncology and onco-hematology). Preferably With 10% and above EBITDA.